Profound Medical Corp. develops and markets interventional MRI medical devices for incision-free tissue ablation. Its recurring news centers on TULSA-PRO® and the TULSA Procedure™, which use real-time MRI guidance, robotically controlled transurethral ultrasound and temperature feedback to ablate prostate tissue in prostate cancer and benign prostatic hyperplasia.
Company updates also cover Sonalleve®, an MRI-guided therapy used for pain palliation of bone metastases, desmoid tumors and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. Recurring developments include financial results, revenue guidance, payer coverage, CAPTAIN post-market clinical data, scientific-meeting presentations, treatment-site adoption milestones and investor conference updates.
Profound Medical Corp. (NASDAQ:PROF) has appointed Cynthia Lavoie, Ph.D., MBA, to its Board of Directors, enhancing its leadership team. Dr. Lavoie brings 18 years of healthcare investment experience, including roles at AllosteRx Capital Management and TVM Life Science Management. Her background in venture capital and corporate governance is expected to strengthen Profound's strategy in customizable medical devices. Profound continues to innovate with TULSA-PRO® and Sonalleve®, advanced technologies for treating prostate cancer and uterine fibroids, respectively.
Profound Medical Corp. (NASDAQ:PROF) reported Q4 2020 revenue of approximately $2.9 million, a 36% year-over-year growth. Total operating expenses rose by 14% to $6.1 million, leading to a net loss of $7.5 million, or $0.38 per share. For the full year, revenue was approximately $7.3 million, up 75% from 2019, while total operating expenses increased by 29% to $22.3 million, resulting in a net loss of $21.6 million, or $1.25 per share. As of December 31, 2020, cash balances stood at $83.9 million. The company aims to enhance U.S. market adoption of its TULSA-PRO® technology despite COVID-19 challenges.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced participation in two investor conferences in March 2021.
Key events include:
- Raymond James 42nd Annual Institutional Investors Conference: March 3, 2021, at 7:30 a.m. ET.
- Cowen 41st Annual Health Care Conference: March 4, 2021, at 9:10 a.m. ET.
Both fireside chats will be live-streamed and archived on the company's website. Profound is known for its incision-free therapies for ablation of diseased tissue, particularly the TULSA-PRO® and Sonalleve® technologies.
Profound Medical Corp. (NASDAQ:PROF) announced its participation in a fireside chat at the BTIG Virtual MedTech Conference on February 18, 2021, at 12:00 p.m. ET. The event will be broadcast live and available for later viewing on the company’s website. Profound specializes in customizable, incision-free therapies for the ablation of diseased tissue, focusing on technologies like TULSA-PRO® and Sonalleve®. TULSA-PRO® targets prostate cancer, while Sonalleve® addresses uterine fibroids and bone metastases. Both technologies hold health regulatory approvals, including CE marking and FDA clearance.
Profound Medical Corp. (NASDAQ: PROF) plans to announce its fourth quarter and full year 2020 financial results on March 2, 2021, post-market close. Management will host a conference call at 4:30 p.m. ET for reviewing these results and discussing business developments. Profound specializes in customizable, incision-free therapies, notably TULSA-PRO® for prostate ablation and Sonalleve® for treating uterine fibroids. The company's technologies are CE marked, FDA cleared, and hold various international approvals.
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) plans to release its third quarter 2020 financial results on November 5, 2020, after market close. A conference call to discuss the findings will occur at 4:30 p.m. ET the same day. Profound is a leading medical device company specializing in customizable, incision-free therapies for tissue ablation. Its key technologies include TULSA-PRO®, designed for radiation-free prostate ablation, and Sonalleve®, which treats uterine fibroids and palliative pain. Both technologies have received necessary regulatory approvals, enhancing the company's market position.
Profound Medical Corp. (NASDAQ:PROF) announced an upcoming presentation at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 11:20 a.m. ET. The company focuses on customizable, incision-free therapies for the ablation of diseased tissue using real-time MRI and ultrasound technology. Their key products include TULSA-PRO, designed for prostate cancer treatment, and Sonalleve, targeting uterine fibroids and pain management. Both technologies have received multiple regulatory approvals, enhancing their market potential.